<p>Frequency of apoptotic cells (A) and IGF-1R (B) and IGFBP-3 (C) expression (densitometry of western blot bands) 24 hours after no treatment (Ctr) or incubation of H9c2 cardiomyocytes with 0.1, 0.5, or 1 μM doxorubicin (Dox). A representative western blot for IGF-1R and IGFBP-3 is shown in (D). *, P <0.05 vs. Ctr; **, P <0.01 vs. Ctr; ***, P <0.001 vs. Ctr. a, P <0.01 vs. Dox 0.5; b, P <0.05 vs. Dox 0.1; c, P <0.001 vs. Dox 0.1.</p
Background/Aims: Doxorubicin is a widely used chemotherapeutic agent, but its clinical use is restri...
<p><b>A.</b> SA-β-Gal activity. Cells were treated for 1 day with doxorubicin (L5 - 50 nM, S3R - 10 ...
Doxorubicin is a chemotherapeutic agent indicated for the treatment of a variety of cancer types, in...
<p>Frequency of apoptotic cells (A) and IGF-1R and IGFBP-3 expression (representative western blot i...
<p>Frequency of apoptotic cells, as assessed by annexin V/propidium iodide staining, 24 hours after ...
Insulin-like growth factor-1 (IGF-1) promotes the survival of cardiomyocytes by activating type 1 IG...
<div><p>Background</p><p>Insulin-like growth factor-1 (IGF-1) promotes the survival of cardiomyocyte...
Insulin-like growth factor-1 (IGF-1) promotes the survival of cardiomyocytes by activating type 1 IG...
Background Insulin-like growth factor-1 (IGF-1) promotes the survival of cardiomyocytes by activatin...
Background: Insulin-like growth factor-1 (IGF-1) promotes the survival of cardiomyocytes by activati...
1A and 1B. Western blotting analysis comparing doxorubicin (DOX) samples with control (CTRL) samples...
<p>(A) Pre-treatment with L-165141decreases the number of doxorubicin-induced apoptotic cells. Bcl6 ...
Background Insulin-like growth factor-1 (IGF-1) promotes the survival of cardiomyocytes by activa...
Background Insulin-like growth factor-1 (IGF-1) promotes the survival of cardiomyocytes by activa...
<p><b>(A)</b> Cell viability under Dox-treatment. CSCs were treated with Dox for 48hrs at the indica...
Background/Aims: Doxorubicin is a widely used chemotherapeutic agent, but its clinical use is restri...
<p><b>A.</b> SA-β-Gal activity. Cells were treated for 1 day with doxorubicin (L5 - 50 nM, S3R - 10 ...
Doxorubicin is a chemotherapeutic agent indicated for the treatment of a variety of cancer types, in...
<p>Frequency of apoptotic cells (A) and IGF-1R and IGFBP-3 expression (representative western blot i...
<p>Frequency of apoptotic cells, as assessed by annexin V/propidium iodide staining, 24 hours after ...
Insulin-like growth factor-1 (IGF-1) promotes the survival of cardiomyocytes by activating type 1 IG...
<div><p>Background</p><p>Insulin-like growth factor-1 (IGF-1) promotes the survival of cardiomyocyte...
Insulin-like growth factor-1 (IGF-1) promotes the survival of cardiomyocytes by activating type 1 IG...
Background Insulin-like growth factor-1 (IGF-1) promotes the survival of cardiomyocytes by activatin...
Background: Insulin-like growth factor-1 (IGF-1) promotes the survival of cardiomyocytes by activati...
1A and 1B. Western blotting analysis comparing doxorubicin (DOX) samples with control (CTRL) samples...
<p>(A) Pre-treatment with L-165141decreases the number of doxorubicin-induced apoptotic cells. Bcl6 ...
Background Insulin-like growth factor-1 (IGF-1) promotes the survival of cardiomyocytes by activa...
Background Insulin-like growth factor-1 (IGF-1) promotes the survival of cardiomyocytes by activa...
<p><b>(A)</b> Cell viability under Dox-treatment. CSCs were treated with Dox for 48hrs at the indica...
Background/Aims: Doxorubicin is a widely used chemotherapeutic agent, but its clinical use is restri...
<p><b>A.</b> SA-β-Gal activity. Cells were treated for 1 day with doxorubicin (L5 - 50 nM, S3R - 10 ...
Doxorubicin is a chemotherapeutic agent indicated for the treatment of a variety of cancer types, in...